Citizens has reaffirmed its stock rating for Celcuity following the release of data from the American Society of Clinical Oncology (ASCO) trial. The firm has assessed the trial results and determined that they align with its previous evaluations of the company's performance. This decision reflects Citizens' ongoing analysis of Celcuity's prospects in the market. The reaffirmation comes as investors closely monitor developments in the biotechnology sector.
Related Articles
Don't miss out on breaking stories and in-depth articles.